The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality

Abstract The relationship between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), diabetes mellitus (DM), and the risk of death in patients with COVID-19 remains controversial. We hypothesized that DM and certain characteristics of the COVID-1...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Mykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2025-11-01
Edice:	Scientific Reports
Témata:	COVID-19 RAAS inhibitors Diabetes mellitus Angiotensin-converting-enzyme inhibitors (ACEIs) Angiotensin II receptor blockers (ARBs) Mortality
On-line přístup:	https://doi.org/10.1038/s41598-025-29757-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!